Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 21 studies | 31% ± 13% | |
plasma cell | 9 studies | 28% ± 9% | |
goblet cell | 9 studies | 29% ± 17% | |
basal cell | 8 studies | 22% ± 8% | |
connective tissue cell | 7 studies | 28% ± 8% | |
club cell | 6 studies | 20% ± 4% | |
endothelial cell | 6 studies | 17% ± 2% | |
epithelial cell | 6 studies | 34% ± 11% | |
smooth muscle cell | 6 studies | 22% ± 5% | |
plasmablast | 5 studies | 38% ± 20% | |
abnormal cell | 5 studies | 22% ± 4% | |
renal alpha-intercalated cell | 5 studies | 44% ± 7% | |
adventitial cell | 5 studies | 52% ± 14% | |
pericyte | 5 studies | 27% ± 14% | |
natural killer cell | 4 studies | 17% ± 2% | |
respiratory goblet cell | 4 studies | 30% ± 9% | |
secretory cell | 4 studies | 22% ± 5% | |
myofibroblast cell | 4 studies | 23% ± 6% | |
ciliated cell | 4 studies | 27% ± 4% | |
IgA plasma cell | 3 studies | 17% ± 0% | |
CD16-positive, CD56-dim natural killer cell, human | 3 studies | 18% ± 2% | |
mucus secreting cell | 3 studies | 30% ± 4% | |
adipocyte | 3 studies | 20% ± 4% | |
mesothelial cell | 3 studies | 21% ± 4% | |
hepatocyte | 3 studies | 38% ± 25% | |
GABAergic neuron | 3 studies | 21% ± 3% | |
glutamatergic neuron | 3 studies | 28% ± 4% | |
endothelial cell of vascular tree | 3 studies | 23% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 5941.03 | 459 / 459 | 100% | 134.91 | 1118 / 1118 |
pancreas | 100% | 3523.84 | 328 / 328 | 100% | 74.94 | 178 / 178 |
stomach | 100% | 4373.46 | 359 / 359 | 100% | 53.89 | 285 / 286 |
liver | 100% | 4462.37 | 226 / 226 | 100% | 78.89 | 404 / 406 |
esophagus | 100% | 4424.57 | 1445 / 1445 | 99% | 46.12 | 182 / 183 |
prostate | 100% | 3312.38 | 244 / 245 | 100% | 181.50 | 501 / 502 |
uterus | 100% | 2158.05 | 170 / 170 | 99% | 70.57 | 455 / 459 |
intestine | 100% | 4876.40 | 966 / 966 | 99% | 69.11 | 522 / 527 |
lung | 99% | 3929.89 | 572 / 578 | 100% | 67.40 | 1154 / 1155 |
bladder | 100% | 4848.62 | 21 / 21 | 98% | 63.98 | 495 / 504 |
ovary | 100% | 4374.31 | 180 / 180 | 98% | 32.63 | 421 / 430 |
thymus | 99% | 3022.12 | 647 / 653 | 97% | 38.27 | 587 / 605 |
skin | 96% | 4656.41 | 1733 / 1809 | 95% | 54.90 | 449 / 472 |
adrenal gland | 100% | 4274.24 | 258 / 258 | 88% | 30.15 | 202 / 230 |
kidney | 98% | 2123.90 | 87 / 89 | 81% | 34.64 | 727 / 901 |
brain | 74% | 1153.79 | 1952 / 2642 | 99% | 31.36 | 696 / 705 |
adipose | 100% | 8376.74 | 1204 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 50.66 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 19.23 | 1 / 1 |
blood vessel | 100% | 4703.48 | 1333 / 1335 | 0% | 0 | 0 / 0 |
muscle | 99% | 2418.91 | 794 / 803 | 0% | 0 | 0 / 0 |
heart | 92% | 2734.22 | 793 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 90% | 29.71 | 26 / 29 |
spleen | 89% | 1564.55 | 214 / 241 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 71% | 17.21 | 57 / 80 |
peripheral blood | 28% | 593.96 | 262 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006048 | Biological process | UDP-N-acetylglucosamine biosynthetic process |
GO_0032481 | Biological process | positive regulation of type I interferon production |
GO_0140374 | Biological process | antiviral innate immune response |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005886 | Cellular component | plasma membrane |
GO_0141090 | Molecular function | protein serine pyrophosphorylase activity |
GO_0052630 | Molecular function | UDP-N-acetylgalactosamine diphosphorylase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0003977 | Molecular function | UDP-N-acetylglucosamine diphosphorylase activity |
Gene name | UAP1 |
Protein name | UDP-N-acetylhexosamine pyrophosphorylase (Antigen X) (AGX) (Protein-pyrophosphorylation enzyme) (EC 2.7.4.-) (Sperm-associated antigen 2) (UDP-N-acetylgalactosamine pyrophosphorylase) (EC 2.7.7.83) (UDP-N-acetylglucosamine pyrophosphorylase) (EC 2.7.7.23) |
Synonyms | SPAG2 |
Description | FUNCTION: Catalyzes the last step in biosynthesis of uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) by converting UTP and glucosamine 1-phosphate (GlcNAc-1-P) to the sugar nucleotide . Also converts UTP and galactosamine 1-phosphate (GalNAc-1-P) into uridine diphosphate-N-acetylgalactosamine (UDP-GalNAc) . In addition to its role in metabolism, acts as a regulator of innate immunity in response to virus infection by mediating pyrophosphorylation of IRF3: catalyzes pyrophosphorylation of IRF3 phosphorylated at 'Ser-386' by TBK1, promoting IRF3 dimerization and activation, leading to type I interferon responses . .; FUNCTION: [Isoform AGX1]: Isoform AGX1 has 2 to 3 times higher activity towards galactosamine 1-phosphate (GalNAc-1-P). .; FUNCTION: [Isoform AGX1]: Isoform AGX2 has 8 times more activity towards glucosamine 1-phosphate (GlcNAc-1-P). . |
Accessions | Q16222 ENST00000367925.6 [Q16222-1] ENST00000367926.9 [Q16222-2] |